Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Pharmaceutical Outsourcing Present and Future

The need for preclinical testing expertise is growing as molecular complexity increases.

Navigating the Preclinical CRO Outsourcing Process

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

A Closer Look at Affinity Ligands

Topic

Articles

Cytovance Biologics anticipates continued expansion plans following acquisition by Hepalink USA

Cytovance Biologics Acquired by Hepalink

With this acquisition, Source BioScience is now able to offer integrated solutions to customers, with environmentally controlled storage in combination with the required up- or downstream analytical testing services.

Source BioScience Completes Acquisition of Select Pharma Laboratories

Anthony M. Cundell is the director of microbiological development and statistics, Global Quality Technology, at Wyeth Pharmaceuticals, 401 N. Middletown Road, Pearl River, NY 10965-1299, tel. 845.602.2497, cundela@wyeth.com

*This article is an opinion piece and does not necessarily represent the views of BioPharm International.

FDA’s Guidance on Quality Metrics: Possible Implications for Contract Testing Laboratories

Companies in the US will now have the opportunity to tap into Hermes Pharma’s technical expertise in effervescent and chewable tablets, instant drinks, lozenges, and orally disintegrating granules (ODGs).

Hermes Pharma Expands Formulation Services to US Market

CMC Biologics will manufacture monoclonal antibodies (mAbs) and provide process development services for the PATH Malaria Vaccine Initiative.

CMC Biologics to Manufacture mAbs for the Treatment of Malaria

Catalent selects advisory board members to complement Redwood Bioscience Scientific Advisory Board.

Catalent Biologics Announces New Advisory Board

Agnes Shanley is senior editor of Pharmaceutical Technology.

Contract research, development, and manufacturing organizations (CROs, CDMOs and CMOs) are embracing lean manufacturing, while Big Pharma is applying it, not so much for inventory management, but to improve supply chain visibility and control.

Getting Comfortable With Lean

FDA issues guidance regarding fees for drug compounding outsourcing facilities.

FDA Outlines Fees for Drug Compounding Companies

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Biopharma companies are outsourcing more jobs to cut costs.

Outsourcing Becoming More Cost Competitive

The YDP30 printer from Sartorius automatically performs thermal transfer or direct thermal printing, without the need to change settings, to meet requirements for fade-resistant printout in regulated areas, such as quality-control laboratories.